Grade Group 4 is a high-grade prostate cancer category corresponding to a Gleason score of 8. It includes Gleason combinations 4+4, 3+5 and 5+3, which contain more abnormal microscopic growth patterns than lower Grade Groups.
This does not mean that the cancer has necessarily spread or cannot be treated with curative intent. Your outlook and treatment options depend on your PSA level, clinical stage, imaging, biopsy findings, general health and personal priorities.
What Does Grade Group 4 Mean?
Grade Group 4 is the fourth category in the five-tier prostate cancer grading system. It indicates high-grade disease with a greater risk of growth, spread or recurrence than Grade Groups 1, 2 and 3.
The Grade Group does not determine your prognosis on its own. Your specialist will combine it with your PSA level, clinical T stage, imaging and other pathology findings to assess your overall risk.
What Is the Gleason Score?
Grade Group 4 corresponds to a Gleason score of 8 and includes 4+4, 3+5 and 5+3. These combinations describe the microscopic growth patterns identified by the pathologist.
The first number generally represents the predominant pattern in the graded tissue. Needle-biopsy reporting also ensures that a clinically important higher-grade pattern is included, so the number order provides information beyond the total score.
Why Does Gleason Number Order Matter?
The first Gleason number represents the predominant cancer pattern in the tissue being graded. The second number records the additional pattern used to calculate the total score, with needle-biopsy rules ensuring that an important higher-grade component is not overlooked.
Gleason 3+5 and 5+3 both total eight, but they contain different proportions of patterns 3 and 5. The presence and amount of pattern 5 may provide additional information about cancer behaviour.
Why Gleason Number Order Matters
| Aspect | What It Means | Example | Why It Matters |
| Predominant pattern | The pattern forming most of the graded cancer is written first | Pattern 3 in 3+5 | Shows the dominant microscopic appearance |
| Additional pattern | Another pattern is included to calculate the score | Pattern 5 in 3+5 | Ensures an important aggressive component is represented |
| Same total score | Different combinations may produce Gleason score 8 | 4+4, 3+5 and 5+3 | The individual patterns provide information beyond the total |
| Pattern 5 | The most abnormal Gleason pattern | Present in 3+5 and 5+3 | May indicate less favourable biological features |
| Grade Group | Every Gleason score of 8 is Grade Group 4 | 4+4=8 | Places the cancer within the five-tier grading system |
| Overall assessment | Grade is combined with PSA and stage | Used to calculate the CPG | Guides treatment discussions |
What Other Pathology Features Matter?
Your pathology report may describe whether Gleason pattern 5, invasive cribriform cancer or intraductal carcinoma is present. These findings can provide additional information about how the cancer may behave.
You can also ask how many biopsy samples contain cancer, how much cancer is present and whether the highest-grade pattern was found in one area or several areas.
How Is Grade Group 4 Diagnosed?
Grade Group 4 is diagnosed when a pathologist examines prostate tissue collected during a biopsy and identifies a Gleason score of 4+4=8, 3+5=8 or 5+3=8. These scores describe the microscopic growth patterns present in the sampled cancer.
Your pathology report may also state how many biopsy samples contain cancer, how much cancer is present and whether Gleason pattern 5, invasive cribriform cancer or intraductal carcinoma has been identified. These findings are considered alongside your PSA level, MRI and clinical stage when assessing your overall risk and treatment options.
Can an MRI Confirm the Grade?
An MRI can help identify suspicious areas in the prostate and guide where biopsy samples should be taken. However, it cannot confirm Grade Group 4 because the diagnosis requires microscopic examination of prostate tissue.
MRI can also help estimate the tumour’s size and location and assess whether there are signs that it extends beyond the prostate. These findings help your clinical team plan further staging investigations and treatment.
Is Grade Group 4 the Same as Stage 4?
No, they are not the same. Grade Group 4 describes the cancer’s microscopic growth patterns and likely biological behaviour, while stage describes its extent, including whether it remains within the prostate, has grown into nearby tissues or has spread to lymph nodes or distant parts of the body.
You can have Grade Group 4 cancer that is still confined to the prostate and potentially treatable with curative intent. Staging tests help you understand whether the cancer has spread beyond the prostate.
Is Grade Group 4 High Risk?
Grade Group 4 is considered a high-risk feature, meaning your cancer may behave more aggressively than lower-grade disease. However, your overall risk is not based on grade alone.
Your PSA level and T stage are also important. Doctors in the UK combine these factors using the Cambridge Prognostic Group system to give you a clearer picture of your risk and guide treatment decisions.
What Is Cambridge Prognostic Group 4?
Grade Group 4 is one of the three features used to define CPG 4 and CPG 5. CPG 4 means that one of the following is present: Grade Group 4, PSA above 20 ng/ml or clinical stage T3.
CPG 5 applies when two or more of those features are present, or when the cancer is Grade Group 5 or stage T4. The CPG system applies to non-metastatic prostate cancer and should not be used once distant spread has been confirmed.
What Is the Outlook?
Grade Group 4 has a greater risk of progression, spread and recurrence than lower Grade Groups. However, localised or locally advanced cancer may still be suitable for treatment with curative intent.
An individual prognosis cannot be predicted from the Grade Group alone. Your Cambridge Prognostic Group, staging investigations, biopsy findings, response to treatment, general health and other clinical factors must also be considered.
Can Grade Group 4 Cancer Be Treated With Curative Intent?
Grade Group 4 prostate cancer may be treated with curative intent when it remains localised or locally advanced and long-term cancer control is considered achievable.
Possible options include radical prostatectomy or radical radiotherapy combined with hormone therapy. Treatment cannot guarantee a cure, and the recommendation depends on the stage, your general health and the expected balance of benefits and side effects.
Is Active Surveillance Suitable?
Active surveillance should not be offered for CPG 4 or CPG 5 localised or locally advanced prostate cancer because these groups have a greater risk of clinically important progression.
Watchful waiting may be appropriate when radical treatment is unlikely to provide sufficient benefit because of age, other health conditions, life expectancy or personal priorities. Watchful waiting focuses on controlling symptoms rather than monitoring with the intention of later curative treatment.
Is Surgery an Option?
Radical prostatectomy may be offered to selected people with CPG 4 or CPG 5 localised or locally advanced non-metastatic prostate cancer when long-term cancer control is considered achievable and surgery is suitable for their health. The operation usually removes the prostate and seminal vesicles, and pelvic lymph nodes may also be removed when there is a meaningful risk of lymph-node involvement.
- Treatment aim: Aims to achieve long-term cancer control by removing the prostate and the cancer within it.
- Surgical procedure: Usually involves removing the prostate and seminal vesicles.
- Cancer suitability: Depends on whether the disease is localised or locally advanced, whether distant spread has been excluded and whether surgery is likely to provide long-term benefit.
- Personal choice: Your preferences, priorities and understanding of potential benefits and side effects are important in decision-making
Whether surgery is suitable for you depends on a combination of medical factors and your personal circumstances. Discussing your options with your healthcare team can help you understand the potential outcomes and choose the approach that best fits your needs.
Will Lymph Nodes Be Removed?
Pelvic lymph nodes may be removed during radical prostatectomy when clinical calculations or imaging suggest a meaningful risk of lymph-node involvement. The decision depends on your PSA, Grade Group, stage and other findings.
Examining the removed lymph nodes provides more accurate pathological staging and may influence recommendations for further treatment. A negative result reduces concern about nodal spread but cannot guarantee that no microscopic cancer remains elsewhere.
Is Radiotherapy an Option?
Radical external beam radiotherapy is an established treatment for suitable people with CPG 4 or CPG 5 localised or locally advanced prostate cancer. Treatment normally targets the prostate and may also include the seminal vesicles according to the location and extent of the cancer.
Pelvic lymph-node radiotherapy may be considered for locally advanced disease when the estimated risk of lymph-node involvement is greater than 15% and neoadjuvant hormone therapy and radical radiotherapy are planned. Possible effects include urinary symptoms, bowel changes, fatigue, erectile dysfunction and side effects from accompanying hormone therapy.
Will Hormone Therapy Be Needed?
NICE recommends combining radical radiotherapy with androgen deprivation therapy for CPG 4 and CPG 5 disease. Six months of hormone therapy should be offered before, during or after external beam radiotherapy.
Continuing hormone therapy for up to three years may be considered after discussing the potential benefits and risks. The appropriate duration depends on the complete cancer assessment, treatment plan, general health and tolerance of side effects.
Can Brachytherapy Be Used?
Brachytherapy may be considered in combination with external beam radiotherapy for selected people with CPG 4 or CPG 5 localised or locally advanced prostate cancer. It should not be offered as the only form of radiotherapy for these groups.
Suitability depends on prostate size, urinary function, cancer extent, previous procedures, general health and local expertise. Androgen deprivation therapy should also form part of the treatment plan when brachytherapy is combined with external beam radiotherapy for CPG 4 or CPG 5 disease.
Is Chemotherapy Sometimes Recommended?
NICE recommends discussing docetaxel with people who have newly diagnosed non-metastatic prostate cancer, are beginning long-term hormone therapy, have no significant comorbidities and have high-risk disease. High-risk criteria include stage T3 or T4, Gleason score 8 to 10 or PSA above 40 ng/ml.
Docetaxel may delay disease progression but can cause significant complications, including infection and febrile neutropenia. Its benefits and risks should be discussed through shared decision-making rather than treating it as a routine requirement for every Grade Group 4 cancer.
How Is Treatment Chosen?
NICE recommends offering radical prostatectomy or radical radiotherapy to suitable people with CPG 4 or CPG 5 non-metastatic prostate cancer when long-term cancer control is considered achievable. Radical radiotherapy is normally combined with androgen deprivation therapy, while brachytherapy or pelvic lymph-node treatment may be considered in selected circumstances.
Your multidisciplinary team will consider your clinical stage, PSA level, imaging, biopsy findings, general health and treatment priorities. The discussion should include the possible effects on urinary, bowel, sexual and hormonal health, as well as the possibility that more than one treatment may be needed.
Myth vs Fact
| Myth | Fact |
| Grade Group 4 means stage 4 cancer. | Grade describes the cancer’s microscopic growth pattern, while stage describes its location and extent of spread. |
| Grade Group 4 means the cancer has already spread. | It may still be contained within or immediately around the prostate. |
| Every Gleason score of 8 has identical microscopic patterns. | Grade Group 4 includes 4+4, 3+5 and 5+3. |
| Grade Group 4 cannot be treated with curative intent. | Surgery or radical radiotherapy may be appropriate for non-metastatic disease. |
| Active surveillance is a standard option. | NICE advises against active surveillance for CPG 4 and CPG 5 disease. |
| Radiotherapy is normally given alone. | It is generally combined with hormone therapy in these groups. |
| Hormone therapy always lasts three years. | Six months is offered, with continuation for up to three years considered individually. |
| Every patient needs chemotherapy. | Docetaxel is discussed only when specific eligibility criteria are met. |
Key Takeaways
- Grade Group 4 corresponds to Gleason score 8.
- It includes Gleason 4+4, 3+5 and 5+3.
- Grade Group 4 is high-grade but is not the same as stage 4 cancer.
- The cancer may still be localised and treated with curative intent.
- Grade Group 4 is CPG 4 when it is the only CPG 4 feature present.
- Two or more CPG 4 features place non-metastatic cancer in CPG 5.
- Active surveillance is not recommended for CPG 4 or CPG 5 disease.
- Surgery or radiotherapy may be offered when long-term control is considered achievable.
- Radiotherapy is normally combined with hormone therapy.
- Docetaxel may be discussed with selected people beginning long-term hormone therapy.
Frequently Asked Questions
- What Does Grade Group 4 Prostate Cancer Mean?
Grade Group 4 corresponds to a Gleason score of 8 and includes 4+4, 3+5 and 5+3. It contains high-grade microscopic growth patterns and has a greater risk of progression than lower Grade Groups, although the cancer may still be localised. - Is Grade Group 4 the Same as Stage 4 Prostate Cancer?
No. Grade Group 4 describes the microscopic growth patterns and likely behaviour of the cancer. Stage describes the location and extent of the disease, including whether it remains within the prostate, has grown into nearby tissues or has spread to lymph nodes or distant parts of the body. - How Is Grade Group 4 Prostate Cancer Diagnosed?
Grade Group 4 is diagnosed through a prostate biopsy, where a pathologist examines your tissue samples under a microscope. The findings are used to calculate your Gleason score and assign your Grade Group. - What Gleason Score Is Grade Group 4?
Grade Group 4 includes Gleason 4+4=8, 3+5=8 and 5+3=8. The individual pattern combination provides additional information about the cancer’s microscopic appearance. - Is Grade Group 4 Prostate Cancer High Risk?
Grade Group 4 is a high-risk feature, but your complete risk depends on PSA and clinical stage. These factors determine whether the cancer is CPG 4 or CPG 5. - Can Grade Group 4 Prostate Cancer Be Cured?
Localised or locally advanced Grade Group 4 cancer may be treated with curative intent. Surgery or radical radiotherapy combined with hormone therapy may be considered, but no treatment can guarantee a cure. - Is Surgery Possible for Grade Group 4 Prostate Cancer?
Radical prostatectomy may be possible when long-term cancer control is considered achievable and surgery is suitable for your health. It may be used for selected localised or locally advanced cancers after multidisciplinary assessment. - Will I Need Hormone Therapy for Grade Group 4 Prostate Cancer?
Hormone therapy is normally combined with radical external beam radiotherapy. NICE recommends offering six months and considering continuation for up to three years for CPG 4 or CPG 5 disease. - Can MRI Detect Grade Group 4 Prostate Cancer?
An MRI can identify suspicious areas, assess tumour size and help guide a biopsy. However, it cannot confirm Grade Group 4 because the diagnosis requires microscopic examination of prostate tissue. - What Factors Affect the Outlook for Grade Group 4 Prostate Cancer?
Your outlook depends on your Grade Group, PSA level, cancer stage, scan results, biopsy findings and overall health. Your specialist will consider all these factors when discussing treatment and prognosis.
Final Thoughts: Understanding Grade Group 4 Prostate Cancer
Grade Group 4 is a high-grade prostate cancer category corresponding to Gleason score 8. It has a greater risk of progression than lower Grade Groups, but it does not automatically mean that the cancer has spread or that treatment with curative intent is no longer possible. Your PSA level, clinical stage, imaging, biopsy findings and Cambridge Prognostic Group provide a more complete assessment.
For suitable people with non-metastatic disease, surgery or radical radiotherapy with hormone therapy may be considered, while docetaxel or brachytherapy may be discussed in selected circumstances. If you are looking for prostate cancer surgery in London, you can reach out to us to arrange a consultation and receive personalised advice about your diagnosis, treatment choices, and recovery.
References
- Aning, J.J., Reilly, G.S., Fowler, S., Challacombe, B., McGrath, J.S., Sooriakumaran, P. et al. (2019) ‘Perioperative and oncological outcomes of radical prostatectomy for high-risk prostate cancer in the UK: an analysis of surgeon-reported data’, BJU International, 124(3), pp. 441–448. Available at: https://pubmed.ncbi.nlm.nih.gov/30681267/
- Cancer Research UK (2025) Cambridge prognostic groups and risk groups for prostate cancer. Last reviewed 22 May 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/stages/cambridge-prognostic-group-cpg
- Cancer Research UK (2025) Chemotherapy for prostate cancer. Last reviewed 28 July 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/metastatic-cancer/treatment/chemotherapy
- Cancer Research UK (2025) Temporary brachytherapy for prostate cancer. Last reviewed 2 July 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/treatment/radiotherapy/brachytherapy/temporary-brachytherapy
- Cancer Research UK (2025) Treatment options for prostate cancer. Last reviewed 18 June 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/treatment/decisions-about-your-treatment
- Epstein, J.I., Egevad, L., Amin, M.B., Delahunt, B., Srigley, J.R. and Humphrey, P.A. (2016) ‘The 2014 International Society of Urological Pathology consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system’, The American Journal of Surgical Pathology, 40(2), pp. 244–252. Available at: https://pubmed.ncbi.nlm.nih.gov/26492179/
- National Institute for Health and Care Excellence (2019) Prostate cancer: diagnosis and management. NICE guideline NG131. Last updated 15 December 2021 and last reviewed 13 August 2025. Available at: https://www.nice.org.uk/guidance/ng131
- NHS (2025) Treatment for prostate cancer. Last reviewed 31 July 2025. Available at: https://www.nhs.uk/conditions/prostate-cancer/treatment/
- Prostate Cancer UK (2023) High dose-rate brachytherapy. Updated January 2023. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/high-dose-rate-brachytherapy
- Prostate Cancer UK (2023) What do my test results mean? Updated August 2023. Available at: https://prostatecanceruk.org/prostate-information-and-support/just-diagnosed/what-do-my-test-results-mean
- Prostate Cancer UK (2024) Surgery: radical prostatectomy. Updated July 2024. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/surgery
- Prostate Cancer UK (2026) External beam radiotherapy. Updated March 2026. Available at: https://prostatecanceruk.org/prostate-information-and-support/treatments/external-beam-radiotherapy